PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
SMMT vs. ARQT
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between SMMT and ARQT is 0.23, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.


-0.50.00.51.00.2

Performance

SMMT vs. ARQT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Summit Therapeutics Inc. (SMMT) and Arcutis Biotherapeutics, Inc. (ARQT). The values are adjusted to include any dividend payments, if applicable.

0.00%50.00%100.00%150.00%200.00%SeptemberOctoberNovemberDecember2025February
116.14%
45.57%
SMMT
ARQT

Key characteristics

Sharpe Ratio

SMMT:

1.40

ARQT:

1.25

Sortino Ratio

SMMT:

4.97

ARQT:

2.10

Omega Ratio

SMMT:

1.64

ARQT:

1.24

Calmar Ratio

SMMT:

4.88

ARQT:

1.15

Martin Ratio

SMMT:

14.84

ARQT:

4.52

Ulcer Index

SMMT:

27.99%

ARQT:

21.51%

Daily Std Dev

SMMT:

298.32%

ARQT:

77.19%

Max Drawdown

SMMT:

-95.75%

ARQT:

-95.02%

Current Drawdown

SMMT:

-35.42%

ARQT:

-64.58%

Fundamentals

Market Cap

SMMT:

$15.21B

ARQT:

$1.53B

EPS

SMMT:

-$0.24

ARQT:

-$1.67

Total Revenue (TTM)

SMMT:

$0.00

ARQT:

$125.18M

Gross Profit (TTM)

SMMT:

-$67.00K

ARQT:

$112.96M

EBITDA (TTM)

SMMT:

-$151.48M

ARQT:

-$109.21M

Returns By Period

In the year-to-date period, SMMT achieves a 15.55% return, which is significantly higher than ARQT's -5.96% return.


SMMT

YTD

15.55%

1M

13.05%

6M

116.14%

1Y

436.98%

5Y*

65.45%

10Y*

N/A

ARQT

YTD

-5.96%

1M

-10.40%

6M

45.56%

1Y

117.61%

5Y*

-11.99%

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

SMMT vs. ARQT — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

SMMT
The Risk-Adjusted Performance Rank of SMMT is 9595
Overall Rank
The Sharpe Ratio Rank of SMMT is 8686
Sharpe Ratio Rank
The Sortino Ratio Rank of SMMT is 9898
Sortino Ratio Rank
The Omega Ratio Rank of SMMT is 9797
Omega Ratio Rank
The Calmar Ratio Rank of SMMT is 9898
Calmar Ratio Rank
The Martin Ratio Rank of SMMT is 9696
Martin Ratio Rank

ARQT
The Risk-Adjusted Performance Rank of ARQT is 8181
Overall Rank
The Sharpe Ratio Rank of ARQT is 8383
Sharpe Ratio Rank
The Sortino Ratio Rank of ARQT is 8282
Sortino Ratio Rank
The Omega Ratio Rank of ARQT is 7777
Omega Ratio Rank
The Calmar Ratio Rank of ARQT is 8282
Calmar Ratio Rank
The Martin Ratio Rank of ARQT is 7979
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

SMMT vs. ARQT - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Summit Therapeutics Inc. (SMMT) and Arcutis Biotherapeutics, Inc. (ARQT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


Sharpe ratio
The chart of Sharpe ratio for SMMT, currently valued at 1.40, compared to the broader market-2.000.002.004.001.401.25
The chart of Sortino ratio for SMMT, currently valued at 4.97, compared to the broader market-4.00-2.000.002.004.004.972.10
The chart of Omega ratio for SMMT, currently valued at 1.64, compared to the broader market0.501.001.502.001.641.24
The chart of Calmar ratio for SMMT, currently valued at 5.28, compared to the broader market0.002.004.006.005.281.15
The chart of Martin ratio for SMMT, currently valued at 14.84, compared to the broader market-10.000.0010.0020.0030.0014.844.52
SMMT
ARQT

The current SMMT Sharpe Ratio is 1.40, which is comparable to the ARQT Sharpe Ratio of 1.25. The chart below compares the historical Sharpe Ratios of SMMT and ARQT, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio0.002.004.006.00SeptemberOctoberNovemberDecember2025February
1.40
1.25
SMMT
ARQT

Dividends

SMMT vs. ARQT - Dividend Comparison

Neither SMMT nor ARQT has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

SMMT vs. ARQT - Drawdown Comparison

The maximum SMMT drawdown since its inception was -95.75%, roughly equal to the maximum ARQT drawdown of -95.02%. Use the drawdown chart below to compare losses from any high point for SMMT and ARQT. For additional features, visit the drawdowns tool.


-80.00%-60.00%-40.00%-20.00%0.00%SeptemberOctoberNovemberDecember2025February
-35.42%
-64.58%
SMMT
ARQT

Volatility

SMMT vs. ARQT - Volatility Comparison

Summit Therapeutics Inc. (SMMT) has a higher volatility of 27.20% compared to Arcutis Biotherapeutics, Inc. (ARQT) at 18.93%. This indicates that SMMT's price experiences larger fluctuations and is considered to be riskier than ARQT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


10.00%20.00%30.00%40.00%50.00%60.00%SeptemberOctoberNovemberDecember2025February
27.20%
18.93%
SMMT
ARQT

Financials

SMMT vs. ARQT - Financials Comparison

This section allows you to compare key financial metrics between Summit Therapeutics Inc. and Arcutis Biotherapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab